Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Metoprolol Succinate prices in Germany, the highest-cost reporting region, corrected 5.0% in Q2 2026, slipping from USD 60.1/KG in Q1 to USD 57.1/KG as metoprolol base and succinic acid synthesis cost softening and post-spring antihypertensive, heart failure, and angina formulation procurement moderation reversed the sustained Q3 2025 through Q1 2026 firming trend. Globally, the average eased from USD 41.92/KG in Q1 to USD 39.82/KG in Q2, a 5.0% decline. For H2 2026, a global average of USD 39.10-43.80/KG is expected, with stabilisation as synthesis costs normalise and steady antihypertensive, heart failure, and angina management sector demand supports the market.
Metoprolol Succinate is the extended-release succinate salt of metoprolol, a cardioselective beta-1 adrenergic receptor antagonist produced by salt formation of metoprolol free base with succinic acid. Metoprolol free base is synthesised from 4-(2-methoxyethyl)phenol through glycidol ether formation and N-alkylation with isopropylamine, and conversion to the succinate salt enables the once-daily extended-release matrix tablet formulation delivering controlled plasma concentrations throughout the dosing interval. The compound’s cardioselective beta-1 receptor blockade reduces heart rate and myocardial oxygen demand without significant beta-2-mediated bronchoconstriction at therapeutic doses. The largest pull comes from heart failure management in patients with reduced ejection fraction, where metoprolol succinate is indicated to reduce cardiovascular mortality and hospitalisation as guideline-directed medical therapy in chronic stable heart failure. Hypertension management and angina pectoris prophylaxis add significant demand. Post-myocardial infarction cardiac protection adds consistent volumes. Metoprolol free base and succinic acid synthesis costs, heart failure guideline-directed therapy adoption and antihypertensive prescription volume growth in low- and middle-income markets, and regional API production capacity all feed into the price.
The balance of supply and demand for Metoprolol Succinate through H2 2026 leans toward stabilisation following the Q2 correction. Metoprolol base and succinic acid synthesis costs are normalising. Heart failure, antihypertensive, and angina management procurement provide consistent demand support at current price levels.
The main upside risk is renewed synthesis cost increases alongside accelerating heart failure management access programme expansion. The main downside risk is continued Chinese and Indian API surplus maintaining competitive price pressure below the forecast range.
| Region | Price Forecast (USD/KG) | Key Driver |
| Global Average | 39.10 - 43.80 | Synthesis cost normalisation and HF/antihypertensive demand |
| United States | 42.10 - 46.80 | Steady heart failure and antihypertensive demand holds firm |
| China | 29.40 - 34.10 | Large API capacity keeps it the most affordable |
| Germany | 54.60 - 59.30 | High synthesis and energy costs keep it the most expensive |
| India | 40.20 - 44.90 | Growing heart failure and export demand holds a firm middle |
US Metoprolol Succinate prices averaged USD 46.5/KG in Q2 2026, down 4.9% from USD 48.9/KG in Q1 2026. Synthesis cost softening and post-spring heart failure and antihypertensive procurement moderation eased the market from the Q1 firming peak.
Why did the price of Metoprolol Succinate change in Q2 2026 in the United States?
Metoprolol base and succinic acid synthesis cost softening reduced the API production floor. Post-spring heart failure, antihypertensive, and angina pectoris procurement moderation reduced buying urgency. Generic competition maintained price normalisation near USD 46.5/KG.
Chinese Metoprolol Succinate prices averaged USD 32.2/KG in Q2 2026, down 5.0% from USD 33.9/KG in Q1 2026, the lowest among the tracked markets. Soft domestic synthesis costs and post-spring heart failure and antihypertensive procurement moderation eased the market.
Why did the price of Metoprolol Succinate change in Q2 2026 in China?
Soft domestic synthesis costs reduced the production floor. Post-spring heart failure and antihypertensive export and domestic procurement moderation reduced buying urgency. Domestic API capacity maintained China as the most affordable source near USD 32.2/KG.
German Metoprolol Succinate prices averaged USD 57.1/KG in Q2 2026, down 5.0% from USD 60.1/KG in Q1 2026, the highest among the tracked markets. Softening synthesis costs and post-spring heart failure and antihypertensive procurement moderation eased the European market from the Q1 firming peak.
Why did the price of Metoprolol Succinate change in Q2 2026 in Germany?
Softening metoprolol base and succinic acid synthesis and energy costs eased the European production floor. Post-spring heart failure, antihypertensive, and angina procurement moderation reduced buying urgency. The market corrected to USD 57.1/KG from the Q1 peak.
Indian Metoprolol Succinate prices averaged USD 44.1/KG in Q2 2026, down 5.0% from USD 46.4/KG in Q1 2026. Soft synthesis import costs and post-spring heart failure and antihypertensive procurement moderation eased the market from the Q1 peak.
Why did the price of Metoprolol Succinate change in Q2 2026 in India?
Soft synthesis import costs reduced the production floor. Post-spring heart failure and antihypertensive procurement moderation eased buying urgency. Price normalisation held the market near USD 44.1/KG after the Q1 firming peak.
US prices averaged USD 48.9/KG in Q1 2026, up 4.0% from Q4 2025. Firmer synthesis costs and heart failure and antihypertensive procurement held the market at the Q1 firming peak.
Why did the price of Metoprolol Succinate change in Q1 2026 in the United States?
Firmer synthesis costs raised the API production floor. Heart failure, antihypertensive, and angina pectoris procurement maintained elevated buying. The market held at USD 48.9/KG before the Q2 synthesis cost softening correction.
Chinese prices averaged USD 33.9/KG in Q1 2026, up 4.0% from Q4 2025. Firmer domestic synthesis costs and post-Lunar New Year heart failure and antihypertensive restocking held the market near USD 33.9/KG.
Why did the price of Metoprolol Succinate change in Q1 2026 in China?
Firmer domestic synthesis costs raised the production floor. Post-Lunar New Year heart failure and antihypertensive procurement maintained elevated buying. The market held at USD 33.9/KG before the Q2 synthesis cost softening correction.
German prices averaged USD 60.1/KG in Q1 2026, up 4.0% from Q4 2025. Firmer synthesis and energy costs and heart failure and antihypertensive procurement held the European market at the Q1 peak.
Why did the price of Metoprolol Succinate change in Q1 2026 in Germany?
Firmer synthesis and energy costs raised the European production floor. Heart failure, antihypertensive, and angina procurement maintained elevated buying. The market held at USD 60.1/KG before the Q2 synthesis cost correction.
Indian prices averaged USD 46.4/KG in Q1 2026, up 4.0% from Q4 2025. Firmer synthesis import costs and heart failure and antihypertensive procurement held the market at the Q1 firming peak.
Why did the price of Metoprolol Succinate change in Q1 2026 in India?
Firmer synthesis import costs raised the production floor. Heart failure and antihypertensive procurement maintained elevated buying. The market held at USD 46.4/KG before the Q2 correction.
Global Metoprolol Succinate prices rose steadily through Q3 2025, Q4 2025, and Q1 2026 on firming synthesis costs and consistent heart failure and antihypertensive demand before correcting in Q2 2026. The average climbed from USD 38.0/KG in Q2 2025 to USD 38.76/KG in Q3, USD 40.31/KG in Q4, and USD 41.92/KG in Q1 2026, then corrected to USD 39.82/KG in Q2 2026, a net gain of about 4.8% over the window. Synthesis cost cycles and heart failure and antihypertensive procurement drove the rising trajectory before the Q2 correction.
| Quarter | Price (USD/KG) | QoQ Change | Direction |
| Q2 2026 | 39.82 | -5.0% | ↓ Falling |
| Q1 2026 | 41.92 | +4.0% | ↑ Rising |
| Q4 2025 | 40.31 | +4.0% | ↑ Rising |
| Q3 2025 | 38.76 | +2.0% | ↑ Rising |
| Q2 2025 | 38.0 | - | - Stable |
| Q3 2026 | In Progress | - | - In Progress |
Metoprolol Succinate prices firmed through 2025 on consistent heart failure and antihypertensive demand. The global average opened near USD 37.3/KG in Q1 2025 and closed at USD 40.31/KG in Q4, a full-year gain of about 8.1%. Synthesis cost firming and growing heart failure guideline-directed medical therapy procurement drove the upward trajectory throughout the year.
US prices firmed from about USD 43.5/KG in Q1 2025 to USD 47.0/KG by Q4, a gain of 8.0%. Consistent heart failure, antihypertensive, and angina demand maintained the upward trend.
Chinese prices firmed from roughly USD 30.2/KG in Q1 2025 to USD 32.6/KG by Q4, a gain of 7.9%. Growing heart failure export and domestic antihypertensive demand drove the firming through the year.
German prices firmed from about USD 53.5/KG in Q1 2025 to USD 57.8/KG by Q4, a gain of 8.0%. Consistent heart failure, antihypertensive, and angina demand and firm synthesis costs supported.
Indian prices firmed from roughly USD 41.4/KG in Q1 2025 to USD 44.6/KG by Q4, a gain of 7.7%. Growing heart failure and antihypertensive export and domestic demand drove firming.
Expert Market Research: Your Source for Real-Time Metoprolol Succinate Price Intelligence
Expert Market Research tracks Metoprolol Succinate prices continuously across every major producing and consuming region. The team traces causation through metoprolol base and succinic acid synthesis economics, heart failure and antihypertensive prescription cycles, and regional API production capacity. Contact Expert Market Research today for Metoprolol Succinate pricing data, bespoke market analysis, and strategic procurement advisory.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Heart failure management in patients with reduced ejection fraction as a guideline-directed medical therapy reducing cardiovascular mortality and hospitalisation takes the largest share, with the succinate salt specifically indicated for chronic stable heart failure. Once-daily sustained-release antihypertensive prescribing and angina pectoris prophylaxis also consume significant volumes, with post-MI cardiac protection adding further demand globally.
The Q2 2026 average was USD 46.5/KG in the United States, USD 32.2/KG in China, USD 57.1/KG in Germany, and USD 44.1/KG in India. Germany remains the highest-priced market after the Q2 correction.
The global average rose to a peak of USD 41.92/KG in Q1 2026 before correcting to USD 39.82/KG in Q2, a 5.0% quarterly decline. Sustained synthesis cost firming through Q1 and post-spring procurement moderation drove the rise-and-correct pattern.
Metoprolol base and succinic acid synthesis cost softening reduced the API production floor. Post-spring heart failure and antihypertensive procurement moderation reduced buying urgency from the Q1 firming peak, allowing the Q2 price correction.
The global average is expected in the USD 39.10 to 43.80/KG range for H2 2026, with stabilisation as synthesis costs normalise and heart failure, antihypertensive, and angina sector demand resumes.
Germany sits highest on synthesis and energy costs, the United States and India hold a firm middle on heart failure and antihypertensive demand, and China prices lowest on domestic API production capacity.
This report is updated monthly. For real-time pricing intelligence, contact the Expert Market Research team directly.
Prices respond mainly to metoprolol base and succinic acid synthesis costs, heart failure and antihypertensive prescribing volume cycles, and heart failure guideline adoption. Synthesis precursor prices and heart failure hospitalisation data are key signals.
China and India hold the largest metoprolol succinate API synthesis capacity. Any synthesis cost shift ripples across markets within one to two quarters.
Buyers can use quarterly trends and forecasts to time heart failure and antihypertensive formulation contracts around synthesis cost cycles, build cover when intermediate signals tighten, and monitor heart failure prescribing volumes as the primary demand signal.
One Year Subscription
One Year Subscription
USD 799
USD 699
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.